ARYx Therapeutics IncOver The Counter Market:ARYX
- LAST PRICE0.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ARYx Therapeutics Inc | 30.0 | 0.0x | --- |
Miravant Medical Technologies | 40.0 | 0.0x | --- |
Arno Therapeutics Inc | 4.9K | 0.0x | --- |
Vaxxinity Inc | 25.4K | 0.0x | --- |
Scopus Biopharma Inc | 12.6K | 0.0x | --- |
Omnimmune Holdings Inc | 940.0 | 0.0x | --- |
Company Information
ARYx Therapeutics, Inc. is a United States-based pharmaceutical Company. The Company is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. It is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.
Contact Information
- Headquarters
- 6300 Dumbarton CirFREMONT, CA, United States 94555
- Phone
- 510-585-2200
- Fax
- 510-585-2202
Executives
- Chairman of the Board, Chief Executive Officer
- Paul Goddard
- Chief Operating Officer
- John Varian
- Vice President - Corporate Affairs, Secretary
- David Nagler
- Director
- Nicholas Simon
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $30.00 |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 33.5M |
ARYx Therapeutics Inc does not pay a dividend. | |
Beta | --- |
EPS | $-0.61 |
Book Value | $-0.10 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
